All Title Author
Keywords Abstract

Factors Associated with Mortality among Multidrug Resistant Tuberculosis MDR/RR-TB Patients in Democratic Republic of Congo

DOI: 10.4236/jtr.2017.54029, PP. 276-291

Keywords: MDR/RR-TB, Mortality, Kinshasa, Factors

Full-Text   Cite this paper   Add to My Lib


Background: Tuberculosis remains a very common infectious disease in Democratic Republic of Congo (DRC). The resistance to drugs worsens the prognosis and the outcome of patients affected tuberculosis and increase their mortality. Objective: To identify factors associated with death among Multidrugs resistant tuberculosis (MDR/RR TB) patients referred to the referential hospital, Centre d’Excellence Damien (CEDA). Materials and Methods: A retrospective cohort study of patients attending health care to the Center CEDA, a referral center for management of MDR/RR-TB in DR Congo. This study included all MDR/RR-TB patients referred from February 1st, 2015 to February 29th, 2017. A multivariate COX regression was performed to identify factors associated with mortality in the target population. Kaplan Meier method described the survival of patients and the comparison of curves was performed by the test of log Rank. Results: 199 patients were included in our study. Male gender was predominant with a sex ratio of 1.3. The mean age of patients was 35.8 ± 13.9 years. Among them, 18 (15.1%) were died. The major complications were Chronicles pulmonary Heart failure (p = 0.035), Chronic respiratory insufficiency (p = 0.004), depression (p = 0.044), undernutrition (p = 0.033), alcohol addiction (p = 0.006) and high smoking (p = 0.019). In multivariated analysis, factors associated to the death were alcohol addiction (HRa = 12.64, 95% CI 2.36 - 14.55, p = 0.003), asthenia (HRa = 4.75, 95% CI 1.56 - 14.50, p < 0.001), pulmonary consolidation (HRa = 10.01 95% CI 2.34 - 12.86, p = 0.02), some chest X-ray abnormalities such as signs of pulmonary fibrosis (HR = 4.7, 95% CI 2.78 - 28.94, p = 0.002) and the Chronic respiratory insufficiency (HRa = 3.77, 95% CI 1.37 - 10.43, p = 0.010). Conclusion: The present retrospective cohort study revealed that structural and functional pulmonary alteration emerged as the main factors associated with mortality among MDR/RR TB patients in Kinshasa. National Tuberculosis Programs should take into account those parameters while defining mortality reduction strategy.


[1]  World Health Organization (2016) Global Tuberculosis Report 2016. WHO, Geneva.
[2]  Rapport du groupe thématique sur la tuberculose pharmacorésistante pour la revue externe à mi-parcours, PNLT RD Congo Décembre 2016.
[3]  Chung-Delgado, K., Guillen-Bravo, S., Revilla-Montag, A. and Bernabe-Ortiz, A. () Mortality among MDR-TB Cases: Comparison with Drug-Susceptible Tuberculosis and Associated Factors. PLoS ONE, 10, e0119332.
[4]  Kashongwe, M.I., Bakebe, M.A., Nguen, O., Kabengele, B.O., Woyam, A., Bidiaka, M.C. and Kayembe, J.M. (2017) Evaluation thérapeutique de la tuberculose pulmonaire à bacille multirésistant: Etude de cohorte historique aux Cliniques Universitaires de Kinshasa. Annales Africaines de Médecine, 10, 2545-2550.
[5]  Kashongwe, M.I., Mbulula, L., Bisuta, F.S., et al. (2015) Profil épidémiologique, bactériologique et évolutif des patients tuberculeux Multirésistants en traitement ambulatoire standardisé de 24 mois à Kinshasa, RD Congo. Revue de pneumologie tropicale, 7ème Congrès de la Saplf, Yaoundé, Octobre 2015, abstract AD1-19, p. 34.
[6]  Guide de prise en charge de la tuberculose PATI-5, Programme National de Lutte contre la Tuberculose en République Démocratique du Congo, 2016.
[7]  Gandhi, N.R., Andrews, J.R., Brust, J.C.M., Montreuil, R., Weissman, D., Heo, M., Moll, A.P., Friedland, G.H. and Shah, N.S. (2012) Risk Factors for Mortality among MDR- and XDR-TB Patients in a High HIV-Prevalence Setting. International Union against Tuberculosis and Lung Disease, 16, 90-97.
[8]  World Health Organization (2016) Chest Radiography in Tuberculosis Detection— Summary of Current WHO Recommendations and Guidance on Programmatic Approaches. WHO Library Cataloguing-in-Publication Data, WHO/HTM/TB/2016.20.
[9]  Bjelland, I., Dahl, A.A., Haug, T.T. and Neckelmann, D. (2002) The Validity of the Hospital Anxiety and Depression Scale: An Updated Literature Review. Journal of Psychosomatic Research, 52, 69-77.
[10]  Organisation Mondiale de la Santé (2016) Guide, lignes directrices unifiées sur la prévention, le diagnostic, le traitement et les soins du VIH pour les populations clé. Bureau régional de l’OMS pour l’Afrique, OMS juin.
[11]  Organisation Mondiale de la Santé (2017) Rapport sur le paludisme dans le monde 2016: Résumé. OMS, Genève. (WHO/HTM/GMP/2017.4)
[12]  Bakebe, A., Kashongwe, I., Mulenga, C., Tshiasuma, M., Kabengele, B., Bisuta, S.F., Makulo, J.R., Kashongwe, Z. and Kayembe, J.-M. (2017) Pulmonary Embolism: Epidemiologic Data and Diagnosis in Kinshasa. The International Journal of Tuberculosis and Lung Disease, 21, 875-879.
[13]  Ferreira, F.L., Bota, D.P., Bross, A., et al. (2001) Serial Evaluation of the SOFA Score to Predict Outcome in Critically Ill Patients. JAMA, 286, 1754-1758.
[14]  Piubello, A., Hassane Harouna, S., Souleymane, M.B., Boukary, I., Morou, S., Daouda, M., et al. (2014) Taux élevé de guérison sans rechute avec un traitement court standardisé de la tuberculose multirésistante au Niger. International Journal of Tuberculosis and Lung Disease, 18, 1188-1194.
[15]  Sterling, T.R., Zhao, Z., Khan, A., Chaisson, R.E., Schluger, N., Mangura, B., et al. (2006) Mortality in a Large Tuberculosis Treatment Trial: Modifiable and Non-Modifiable Risk Factors. The International Journal of Tuberculosis and Lung Disease, 10, 542-549.
[16]  Amnuaiphon, W., Anuwatnonthakate, A., Nuyongphak, P., et al. (2009) Factors Associated with Death among HIV-Uninfected TB Patients in Thailand, 2004-2006. Tropical Medicine & International Health, 14, 1338-1346.
[17]  Horne, et al. (2010) Factors Associated with Mortality in Patients with Tuberculosis. BMC Infectious Diseases, 10, 258.
[18]  Georghiou, S.B., Seifert, M., Catanzaro, D.G., Garfein, R.S. and Rodwell, T.C. (2017) Increased Tuberculosis Patient Mortality Associated with Mycobacterium tuberculosis Mutations Conferring Resistance to Second-Line Antituberculous Drugs. Journal of Clinical Microbiology, 55, 1928-1937.
[19]  Theron, G., Peter, J., Richardson, M., Barnard, M., Donegan, S., Warren, R., Steingart, K.R. and Dheda, K. (2014) The Diagnostic Accuracy of the GenoType MTBDRslassay for the Detection of Resistance to Second-Line Anti-Tuberculosis Drugs. Cochrane Database of Systematic Reviews, No. 10, CD010705.
[20]  Clouse, K., et al. (2012) Implementation of Xpert MTB/RIF for Routine Point-of-Care Diagnosis of Tuberculosis at the Primary Care Level. South African Medical Journal, 102, 805-807.
[21]  Isanaka, S., Mugusi, F., Urassa, W., Willett, W.C., Bosch, R.J., Villamor, E., Spiegelman, D., Duggan, C. and Fawzi, W.W. (2012) Iron Deficiency and Anemia Predict Mortality in Patients with Tuberculosis. Journal of Nutrition, 142, 350-357.
[22]  Waitt, C.J. and Squire, S.B. (2011) A Systematic Review of Risk Factors for Death in Adults during and after Tuberculosis Treatment. International Journal of Tuberculosis and Lung Disease, 15, 871-885.
[23]  Kawa, S.G., Gilarmo, R.H., et al. (2006) Tuberculosis Mortality, Drug Resistance, and Infectiousness in Patient with and without HIV Infection in PERU. The American Journal of Tropical Medicine and Hygiene, 75, 1027-1033.
[24]  Reed, G.W., Choi, H., Lee, S.Y., Lee, M., Kim, Y., et al. (2013) Impact of Diabetes and Smoking on Mortality in Tuberculosis. PLoS ONE, 8, e58044.
[25]  Baker, et al. (2011) The Impact of Diabetes on Tuberculosis Treatment Outcomes: A Systematic Review. BMC Medicine, 9, 81.
[26]  Pascopella, L., Barry, P.M., Flood, J. and Kathryn, D.R. (2014) Death with TB in California, 1994-2008. Open Forum Infectious Diseases, 1, ofu090.
[27]  Ralph, A.P., Kenangalem, E., Waramori, G., Pontororing, G.J., Sandjaja, et al. (2013) High Morbidity during Treatment and Residual Pulmonary Disability in Pulmonary Tuberculosis: Under-Recognised Phenomena. PLoS ONE, 8, e80302.
[28]  Javaid, A., Shaheen, Z., Shafqat, M., Khan, A.H. and Ahmad, N. (2017) Risk Factors for High Death and Loss-to-Follow-up Rates among Patients with Multidrug-Resistant Tuberculosis at a Programmatic Management Unit. American Journal of Infection Control, 45, 190-193.
[29]  Danesh, J., et al. (2016) Body-Mass Index and All-Cause Mortality: Individual Participant-Data Meta-Analysis of 239 Prospective Studies in Four Continents. The Lancet, 388, 776-786.
[30]  Liu, C.H., Li, L., Chen, Z., Wang, Q., Hu, Y.L., et al. (2011) Characteristics and Treatment Outcomes of Patients with MDR and XDR Tuberculosis in a TB Referral Hospital in Beijing: A 13-Year Experience. PLoS ONE, 6, e19399.
[31]  Ugarte, G.C., Ruiz, P., Zamudio, C., Canaza, L., Otero, L., Kruger, H. and Seas, C. (2013) Association of Major Depressive Episode with Negative Outcomes of Tuberculosis Treatment. PLoS ONE, 8, e69514.
[32]  Oh, K.H., Choi, H., Kim, E.J. and Cho, S.I. (2017) Depression and Risk of Tuberculosis: A Nationwide Population Based Cohort Study. The International Journal of Tuberculosis and Lung Disease, 21, 804-809.


comments powered by Disqus